TaylorJBergerBAnderson-HarperHGrimleyD. Pharmacists' readiness to assess consumers' over-the-counter product selections. J Am Pharm Assoc (Wash)2000;40:487–94.
2.
TaylorJLandryELalondeLTsuyukiRT. Results of a national survey on over-the-counter medicines, Part 1: Pharmacist opinion on current scheduling status. Can Pharm J2012;145:40–4.
3.
MadhavenS. Factors influencing pharmacists' preference for the legal classification of Rx-to-OTC switched drug products. J Clin Pharm Ther1993;18:281–90.
4.
ShefcheckSLThomasJ. Consumers' perceptions of access to medications and attitudes toward regulatory options. J Soc Adm Pharm1998;15:149–63.
5.
IsacsonDBingeforsC. On Rx switches and access to over-the-counter drugs in Sweden. J Soc Adm Pharm1999;16:13–25.
6.
BlenkinsoppJGathogaLO'ConnellKOTC simvastatin supply: what changes in practice and education do pharmacists want?Pharm J2004;273(7311):191–3.
7.
StewartDJohnDCunninghamSA comparison of community pharmacists' views of over-the-counter omeprazole and simvastatin. Pharmacoepidemiol Drug Saf2007;16:1290–7.
StewartDCunninghamITHansfordDGeneral practitioners' views and experiences of over-the-counter simvastatin in Scotland. Br J Clin Pharmacol2010;70:356–9.
10.
HuntTLCulbertsonVLErramouspeJCaspersonK. Perceptions of practicing pharmacists in Idaho about a potential behind-the-counter drug program. Ann Pharmacother2010;44:1403–9.
11.
TsaiACMortonSCKeelerEB. A meta-analysis of interventions to improve chronic illness care. A RAND Health Program; 2005. Available: www.rand.org/pubs/working_papers/WR290.html (accessed July 13, 2010).
12.
AvornJMonetteJLacourAPersistence of use of lipid-lowering medications. A cross-national study. JAMA1998;279:1458–62.
13.
MorellRWParkDCKidderDPMartinM. Adherence to antihypertensive therapy medications across life span. Gerontologist1997;37:609–19.
14.
JoffresMRGhadirianPFodorJGAwareness, treatment, and control of hypertension in Canada. Am J Hypertens1997;10(10 Pt 1):1097–102.
15.
JackeviciusCAMamdaniMTuJV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA2002;288:462–7.
16.
BarhamAHGoffDCJr.ChenHAppropriateness of cholesterol management in primary care by sex and level of cardiovascular risk. Prev Cardiol2009;12:95–101.
17.
HackamDGLeiterLAYanATMissed opportunities for the secondary prevention of cardiovascular disease in Canada. Can J Cardiol2007;23:1124–30.
18.
McCaigDHansfordDJohnDReclassification of omeprazole: a survey of community early experiences and views. Int J Pharm Pract2008;16:23–8.
19.
VilleneuveJLamarreDLussierMTPhysician-pharmacist collaborative care for dyslipidemia patients: knowledge and skills of community pharmacists. J Contin Educ Health Prof2009;29:201–8.
20.
VilleneuveJGenestJBlaisLA cluster randomized controlled Trial to Evaluate an Ambulatory primary care Management program for patients with dyslipidemia: the TEAM study. CMAJ2010;182:447–55.
21.
LalondeLHudonEGoudreauJPhysician-pharmacist collaborative care in dyslipidemia management: the perception of clinicians and patients. Res Social Adm Pharm2011;7:233–45.
